JPM-TMT joint project manager David Hough said the drug showed that it can mitigate flu symptoms by interfering with the influenza replication process.
In earlier animal studies and Phase 1 human clinical trials, Favipiravir has shown positive results.
The Phase 3 clinical studies of Favipiravir drug is expected to commence as early as fall 2012.
JPM-TMT facilitates the advanced development and acquisition of broad-spectrum medical countermeasures and systems to improve biodefense response capability.